This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This slow and steady concept gained more validation in June when the company announced early but promising data from a phase 2 trial of its MEK inhibitor atebimetinib combined with chemotherapy, which showed a six-month 94% overall survival in pancreatic cancer.
At ASCO, one of the most talked-about studies was a late-stage trial in which the treatment outperformed chemotherapy as a first-line drug. As we move earlier, almost all of our trials will be in combination with different [immuno-oncology] drugs and … even chemotherapy drugs,” Keller said. “As
The findings of the DeLLphi-304 study demonstrated improved OS of tarlatamab compared with single-agent chemotherapy (median OS [mOS], 13.6 The updated definition for HRMM is increasingly important as there is an increased focus on how to improve outcomes for patients with HRMM, functional HRMM, and true extramedullary disease.
Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. For this application, the FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic.
In 2023, Dr. Reddy’s entered into a licensing and commercialization agreement with Shanghai Junshi Biosciences for toripalimab. The drug is also approved as a monotherapy for patients experiencing disease progression after platinum-based chemotherapy.
Study Overview Researchers conducted a retrospective chart review of 80 patients aged 12 or older within Intermountain Health who were diagnosed with asthma between December 2022 and December 2023. To ensure continuity of care, patients included had seen a primary care provider both in the year prior to and following their diagnosis.
In 2023, Dr. Reddy’s entered into a license and commercialisation agreement with Shanghai Junshi Biosciences for Toripalimab. The standard of care for RM-NPC in India before Toripalimab was chemotherapy (gemcitabine and cisplatin). ” The Lancet Regional Health-Southeast Asia 12 (2023). Nat Med 27, 1536–1543 (2021).
Approximately 40% to 80% of patients with cancer who are assigned female at birth face possible infertility as a result of their cancer treatments, such as chemotherapy, radiation, and surgery. An additional 15% to 30% of cancer survivors who are assigned male at birth also face infertility as a result of chemotherapy.
Results American Oncology Network (AON) Pharmacy collected data on waste and cost avoidance from February 2023 to September 2023. If a discrepancy is found, the pharmacy nurses will hold the shipment, and a clinical intervention will be communicated to the provider. During this time frame, the pharmacy documented 152 interventions.
From 2003 to 2023, 943 drugs were approved through the 505(b)(2) pathway. As of January 1, 2023, CMS has begun issuing unique J-codes to 505(b)(2) drugs dating back to 2003. “In However, 505(b)(2) drugs have been available since the 1980s.
Clinical Applications and Economic Impacts Biologics have significantly impacted cancer therapies by targeting cancer cells more specifically and reducing adverse events compared with traditional chemotherapy, Darkow noted. billion worth in savings in 2023 and $36 billion since the first biosimilar entered the market in 2015.
Blood cancer patients are usually at higher risk due to prior chemotherapy, and maybe we don’t need the same kind of prophylactic medications for solid tumor patients. I think we’re getting to the point now where hematology and oncology both need services that can manage these types of side effects. The infection risks are a little different.
Benmelstobart (TQB2450; Chia Tai Tianqing Pharmaceutical Group Co, Ltd) in combination with chemotherapy followed by sequential combination with anlotinib (Catequentinib; Advenchen Laboratories) led to significant improvements in progression-free survival (PFS), with a manageable safety profile. months versus 7.79 months with tislelizumab.
Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy. A 67% FN rate difference between pegfilgrastim and filgrastim was observed in patients with transportation barriers.
Although improved clinical outcomes with the addition of chemotherapy to ICI have been recorded for some patients, there is ongoing research to understand how prognostic factors (eg, smoking history, tumor histology, performance status) can provide some predictive values for patient response to ICI therapy. months) and 6.4 months).
Eligible patients include adults (≥ 18 years) diagnosed with CML receiving imatinib as first-line therapy for more than 1 month between 2008 and 2023. Materials and Methods This retrospective observational study utilized the Carolina Data Warehouse for Health electronic health record (EHR) database.
Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. Subscribe Now!
6 Chimeric antigen receptor (CAR) cell therapies ranked 10th with 795 candidates, holding steady from 2023. The approval of the first CRISPR-Cas9-based therapy in 2023 has accelerated efforts toward allogeneic, off-the-shelf CAR T products. 6 CAR T-cell therapies continue to dominate the genetically modified space. 2024;45(5):406-418.
Yes, we currently have antibody-drug conjugates that are conjugated to a cytotoxic chemotherapy. So are there oncogenic proteins that we can actually target that we couldn’t traditionally target with just a small molecule inhibitor? We look at ADCs. Unfortunately, these drugs are quite toxic.
SHOW MORE Nivolumab (Opdivo) and chemotherapy demonstrated an overall survival benefit at 5 years, affirming its role as a standard of care option. 1,2 Nivolumab and chemotherapy is a standard of care option for resectable non-small cell lung cancer.
Around late 2023, a friend was diagnosed with metastatic colorectal cancer at 46 years old. After learning of his diagnosis, our relationship shifted from small talk at school events to detailed discussions in an infusion center setting about chemotherapy, immunotherapy, clinical trials, alternative medicines, and anticipated adverse effects.
Vitamin D supplementation increased 25-hydroxyvitamin-D levels significantly, suggesting a potential role in enhancing chemotherapy effectiveness. The study's findings support further research with larger samples to explore vitamin D's impact on chemotherapy and breast cancer remission likelihood.
I think it’ll be chemotherapy—maybe their cells being given outpatient—and then, as we hit their hardest time or their highest risk for either febrile neutropenia or mucositis or even some of the toxicities from the chemotherapy, we have them inpatient until we feel comfortable, and then transition it so that it could be all outpatient.
Updated March 20, 2023. Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. But doing so requires a new kind of expertise that spans science, strategy, and systems thinking.
Additionally, patients may have received prior chemotherapy for advanced disease. Updated October 30, 2023. Additionally, taletrectinib was granted priority review, breakthrough designation, and orphan drug designation for this indication. Accessed June 11, 2025. ClinicalTrials.gov identifier: NCT04395677. Accessed June 11, 2025.
The injection is claimed to be the first and only approved in the UK and European Union (EU) for preventing cisplatin chemotherapy-induced ototoxicity (hearing loss) in individuals aged one month to under 18 years with non-metastatic, localised solid tumours. InOctober 2023, the product was approved in the UKunder the brand name Pedmarqsi.
Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Notably, priorities have shifted since 2023 in favour of greater competitiveness, he adds. Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence. Sign up for our daily news round-up!
.” In a Q&A with EPR last year, Hoppin and Ratio’s Director, President and Chief Scientific Officer, Dr John Babich, described that “there is great hope of this class of drug specifically to work in conjunction with immunotherapeutics, given the lack of toxicity of radiopharmaceuticals in general compared to most chemotherapies.”
Mok : Right now, we have a lot of chemotherapy being used, but there are many more novel treatments being studied, especially in earlier lines of treatment. Bispecifics are moving up in the lymphoma space, and these newer therapies may have some synergistic effects with chemotherapy. REFERENCES 1. Updated August 18, 2021.
Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Reports Future of Pharma - Looking Ahead to 2023 Data Insights The gold standard of business intelligence. Reports Future of Pharma - Looking Ahead to 2023 Data Insights The gold standard of business intelligence.
1 Scientific evidence between January 1, 2016, and January 31, 2023, was included in the study. This was assessed by analyzing real-world pharmacoepidemiological data and conducting a systematic review and meta-analysis to further quantify this risk. Subscribe Now!
TRE-515 Combined With a Radiopharmaceutical As a precision cancer treatment designed for adults with PSMA-positive mCRPC, lutetium Lu 177 vipivotide tetraxetan is used after individuals have undergone other treatments like androgen receptor pathway inhibition and taxane-based chemotherapy.
Antibiotics have long been essential in treating common infections and supporting complex medical interventions like surgeries, cancer chemotherapy, and organ transplants. However, the misuse and overuse of these critical drugs have catalysed a global health crisis: antimicrobial resistance (AMR).
1 Biomarker testing is relatively new in the treatment landscape for NSCLC but has proven incredibly important for personalizing patient care, transforming from a generic chemotherapy approach to a highly personalized, genomically driven treatment strategy. For advanced disease, chemotherapy was the standard.
Go deeper with GlobalData Reports LOA and PTSR Model - Denosumab Biosimilar in Bone Metastasis Reports LOA and PTSR Model - Denosumab Biosimilar in Chemotherapy Effects Data Insights The gold standard of business intelligence. By inhibiting RANKL, denosumab hampers the bone degradation process, bolstering bone density and strength.
Akeega has been approved in Europe for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with steroid hormone prednisolone since 2023. J&J is now attempting to widen the drug’s application to patients with metastatic hormone-sensitive prostate cancer (mHSPC).
The National Institute for Health and Care Excellence (NICE) has recommended Lynparza (olaparib) for adults with HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations after chemotherapy. months with just standard chemotherapy. months, compared to 4.2
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content